



23<sup>rd</sup> International Colloquium on Lung and Airway Fibrosis  
 10-14 October 2025 | Darling Island Wharf | Sydney, Australia

## SCIENTIFIC PROGRAM

### Saturday 10 October 2026

<b>1400 – 1730</b>	<b>Welcome session</b>	<b>Tamera Corte</b>
1400 – 1500	Afternoon tea and registration	
1500 – 1510	Welcome to ICLAF and committee introductions (10)	Tamera Corte
1510 – 1530	Welcome to Country (20)	
1530 – 1545	Consumer Perspective (15)	Brendan Pickles
1545 – 1550	Introduction to plenary speaker (5)	
1550 – 1630	Plenary: The silicosis epidemic and the Australian response (25+15) Ryan Hoy	
1630 – 1635	Introduction to Geoff Laurent Lecture (5)	
1635 – 1715	Geoff Laurent Lecture: Fibrosis of the future (25+15)	Patricia Sime
1715 – 1720	Wrap up and the week ahead (5)	
<b>1720</b>	<b>Welcome reception</b>	

### Sunday 11 October 2026

<b>Session 1</b>	<b>Redefining ILD to drive progress</b>	<b>Daniel Chambers</b>
<b>815 – 1000</b>	Chair:	
815 – 820	Welcome (5)	
820 – 840	Beyond aetiology and morphology for the future (15+5)	Chris Ryerson
840 – 900	Understanding BIP - is this a new entity? (15+5)	Martin Kolb
900 – 920	Discussion (20)	All
920 – 940	Novel approaches to modelling lung function (15+5)	Margaret Salisbury
940 – 1000	Leveraging registries in the modern era (15+5)	Jeremy Wrobel
<b>1000 – 1030</b>	<b>Morning break</b>	
<b>Session 2</b>	<b>Understanding ageing to crack pulmonary fibrosis</b>	
<b>1030 – 1200</b>	Chair:	
1030 – 1055	Concepts of biological age (20+5)	Ana Mora
1055 – 1120	Anti-ageing strategies in pulmonary fibrosis (20+5)	Louise Hecker
1120 – 1130	Clonal haematopoiesis (7+3)	Isis Fernandez
1130 – 1140	Abstract 1 (7+3)	
1140 – 1150	Abstract 2 (7+3)	
1150 – 1200	Abstract 3 (7+3)	
<b>1200 – 1300</b>	<b>Lunch break</b>	
<b>Session 3</b>	<b>Poster discussion series</b>	
<b>1300 – 1530</b>	Chair:	
<b>1500 – 1530</b>	<b>Afternoon break (concurrent with poster session)</b>	



**Session 4 What we have learned about genetics and ILD**

**1530 – 1735**

Chair:

1530 – 1535	Introduction	
1535 – 1600	Familial PF – Global insights (20+5)	Raphael Borie
1600 – 1620	Rare variants – moving the field forward (15+5)	Joanne Dickinson
1620 – 1640	Global approach to understanding common variants in PF (15+5)	Anna Peljto
1640 – 1650	Abstract 1 (7+3)	
1650 – 1700	Abstract 2 (7+3)	
1700 – 1710	Abstract 3 (7+3)	
1710 – 1720	Abstract 4 (7+3)	
1720 – 1735	Clinical genetics in pulmonary fibrosis (10+5)	Christine Garcia

**1800 – 2100 Casual dinner**

**Monday 12 October 2026**

**Nicole Goh**

**Session 5 Taking advanced imaging the next step**

**820 – 1000**

Chair:

820 – 830	Welcome	
830 – 855	The future of imaging AI in ILD (20+5)	Stephen Humphries
855 – 915	PET scans to improve understanding of ILD (15+5)	Sydney Montesi
915 – 9:25	Abstract 1 (7+3)	
930 – 940	Abstract 2 (7+3)	
940 – 950	Abstract 3 (7+3)	
950 – 1000	Abstract 4 (7+3)	

**1000 – 1030 Morning break**

**Session 6 Understanding and targeting cellular cross-talk in the fibrotic niche**

**1030 – 1200**

Chair:

1030 – 1050	Link between biology and structure in pulmonary fibrosis (15+5)	Tillie Hackett
1050 – 1110	Distinct pathologic macrophages and fibroblasts in IPF and silicosis (15+5)	Dan Chambers
1110 – 1130	Neural regulation of fibrosis (15+5)	Erica Herzog
1130 – 1140	Abstract 1 (7+3)	
1140 – 1150	Abstract 2 (7+3)	
1150 – 1200	Abstract 3 (7+3)	

**Session 7 Dan Rose Session – Improving quality of life for PF patients**

**1200 – 1330**

Chair:

1200 – 1210	Integrating consumer perspectives in your research (7+3)	Anne Holland
1210 – 1215	Introduction to Dan Rose Lecture (5)	TBC
1215 – 1245	Dan Rose Lecture (25+5)	Jeff Swigris
1245 – 1330	Round table: Consumers and the future of PF research (45)	Tania Hyde
	Mark Brooke, Anne Holland, Steve Jones, Jeff Swigris	

**1330 – Lunch and afternoon activities**

**1800 – Optional gathering**



## Tuesday 13 October 2026

Steve Mutsaers

<b>Session 8</b> <b>820 – 1010</b>	<b>Novel cellular and molecular mechanisms of PF pathogenesis and progression</b> Chair:	
820 – 830	Welcome	
830 – 850	Extending beyond characterization of fibroblast subtypes (15+5)	Dianhua Jiang
850 – 910	Pro-fibrotic epithelial phenotypes (15+5)	Rachel Zemans
910 – 930	Surfactant protein C and fibrosis (15+5)	Jenny Dickens
930 – 950	The role of the endothelium and vasculature in PF (15+5)	Sukhwinder Sohal
950 – 1000	Abstract 1 (7+3)	
1000 – 1010	Abstract 2 (7+3)	
<b>1010 – 1040</b>	<b>Morning break</b>	
<b>Session 9</b> <b>1040 – 1210</b>	<b>We are what we breathe? The environmental impact on fibrosis</b> Chair:	
1040 – 1105	Incidental lifetime exposures: what do we tell patients and governments? (20+5)	Kerri Johannson
1105 – 1130	How does our environment impact PF on a cellular level (20+5)	Jennifer Casey
1130 – 1140	Wildfires and pulmonary fibrosis (7+3)	Paris Papagianis
1140 – 1200	Abstract 1 (7+3)	
1200 – 1210	Abstract 2 (7+3)	
<b>1210 – 1300</b>	<b>Lunch break</b>	
<b>Session 10</b> <b>1300 – 1400</b>	<b>Andy Tager Session</b> Chair:	
1300 – 1305	Introduction to Andy Tager Lecture	TBC
1305 – 1330	Andy Tager Lecture: Short telomere syndrome (25+5)	Paul Wolters
1330 – 1345	Functional insights into TERT variants (10+5)	Chris Reilly
1345 – 1400	Discussion (15)	All
<b>Session 11</b> <b>1400 – 1540</b>	<b>Therapeutic advances in pulmonary fibrosis</b> Chair:	
1400 – 1420	Beyond bleomycin: Building better models for PF (15+5)	Janette Burgess
1420 – 1445	New therapies on the horizon (20+5)	Toby Maher
1445 – 1505	Addressing cough in ILD (15+5)	Surinder Birring
1505 – 1530	Treating PH in ILD in the current era (20 +5)	Laura Price
1530 – 1540	Abstract 1 (7+3)	
<b>1540 – 1610</b>	<b>Afternoon break</b>	
<b>Session 12</b> <b>1610 – 1730</b>	<b>Immune mediated mechanisms of lung fibrosis</b> Chair:	
1610 – 1630	What can we learn from the vasculitis/IPF overlap? (15+5)	Bruno Crestani
1630 – 1650	Understanding disease pathways in Scleroderma ILD (15+5)	TBC
1650 – 1710	IPAF: Have we moved on (15+5)	Mary Streck
1710 – 1720	Abstract 1 (7+3)	



1720 – 1730 Abstract 2 (7+3)

**1900 – 2100 Colloquium dinner and awards ceremony (times TBC)**

**Wednesday 14 October 2026**

**Cecilia Prele**

**Session 13 Opening the flood gates: Interstitial Lung Abnormalities**

**820 – 1000**

Chair:

820 – 830

Welcome

830 – 850

Redefining ILA and early ILD - beyond the guidelines (15+5)

Anna Podolanczuk

850 – 905

Mechanisms for progression from ILA to ILD (10+5)

Jonathan Rose

905 – 920

Are we ready for screening in prime-time? (10+5)

Mandana Nikpour

920 – 940

What treatments are in the pipeline for ILA and early ILD? (15+5)

Matt Hunninghake

940 – 950

Abstract 1 (7+3)

950 – 1000

Abstract 2 (7+3)

**1000 – 1030**

**Morning break**

**Session 14**

**More than biomarkers - moving OMICS to the clinic**

**1030 – 1200**

Chair:

1030 – 1050

Using single cell sequencing for drug targeting in ILD (15+5)

Ivan Rosas

1050 – 1100

Are we ready to use OMICS in the clinic? Update from PRIME-PF (7+3)

Fernando Martinez

1100 – 1120

Using spatial transcriptomics to understand PF pathogenesis (15+5)

Nicholas Banovich

1120 – 1130

Abstract 1 (7+3)

1130 – 1140

Abstract 2 (7+3)

1140 – 1150

Abstract 3 (7+3)

1150 – 1200

Abstract 4 (7+3)

1200 – 1215

Closing remarks from consumer participants

Steve Jones, Debra Murray

1215 – 1230

Wrap up and hand over

Tamera Corte, Maria Molina Molina

**1230 – 1400**

**Lunch and departures**